Abstract:The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects on glycemic control and body weight regulation, led to efforts to extend its half-life and make it therapeutically effective in people with type 2 diabetes (T2D). The development of short- and then long-acting GLP-1 receptor agonists (GLP-1RAs) followed. Our article charts the discovery and development of the long-acting GLP-1 analogs liraglutide and, subsequently, semaglutide. We examine the chemistry employed in designing liraglutide and semaglutide, the human and non-human studies used to investigate their cellular targets and pharmacological effects, and ongoing investigations into new applications and formulations of these drugs. Reversible binding to albumin was used for the systemic protraction of liraglutide and semaglutide, with optimal fatty acid and linker combinations identified to maximize albumin binding while maintaining GLP-1 receptor (GLP-1R) potency. GLP-1RAs mediate their effects via this receptor, which is expressed in the pancreas, gastrointestinal tract, heart, lungs, kidneys, and brain. GLP-1Rs in the pancreas and brain have been shown to account for the respective improvements in glycemic control and body weight that are evident with liraglutide and semaglutide. Both liraglutide and semaglutide also positively affect cardiovascular (CV) outcomes in individuals with T2D, although the precise mechanism is still being explored. Significant weight loss, through an effect to reduce energy intake, led to the approval of liraglutide (3.0 mg) for the treatment of obesity, an indication currently under investigation with semaglutide. Other ongoing investigations with semaglutide include the treatment of non-alcoholic fatty liver disease (NASH) and its use in an oral formulation for the treatment of T2D. In summary, rational design has led to the development of two long-acting GLP-1 analogs, liraglutide and semaglutide, that have made a vast contribution to the management of T2D in terms of improvements in glycemic control, body weight, blood pressure, lipids, beta-cell function, and CV outcomes. Furthermore, the development of an oral formulation for semaglutide may provide individuals with additional benefits in relation to treatment adherence. In addition to T2D, liraglutide is used in the treatment of obesity, while semaglutide is currently under investigation for use in obesity and NASH.

The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity

Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity

Winning researchers unlocked GLP-1 drugs for obesity

Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions

Obesity-drug pioneers win prestigious Lasker Award for medical science

How GLP-1 went from being a hard-to-handle hormone to a blockbuster success

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

GLP-1 and Amylin in the Treatment of Obesity

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges

Are GLP-1R agonists the long-sought-after panacea for obesity?

The Discovery and Development of Liraglutide and Semaglutide

Transforming obesity: The advancement of multi-receptor drugs

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity